Embed Size (px)
Citation preview
WHO/BS/2015.2267
ENGLISH ONLY
EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION
Report on the WHO collaborative study to establish the 1st International Standard for
anti-EV71 serum (Human)
Gillian Cooper
1,4, Qunying Mao
2, Laura Crawt
1, Yiping Wang
2, Thomas Dougall
3
Peter Rigsby3, Zhenglun Liang
2, Miao Xu
2, Philip Minor
1, Junzhi Wang
2 and
Javier Martin1,4
and study participants (see Appendix 1)
Division of Virology1 and Biostatistics
3
National Institute for Biological Standards and Control (NIBSC),
South Mimms, Potters Bar, Herts, EN6 3QG, UK
National Institute for Food and Drug Control (NIFDC), Beijing 100050, China2
4Study Coordinators; Tel: +44 1707 641000, Fax: +44 1707 641050
E-mail: [email protected]
NOTE:
This document has been prepared for the purpose of inviting comments and suggestions on
the proposals contained therein, which will then be considered by the Expert Committee on
Biological Standardization (ECBS). Comments MUST be received by 14 September 2015
and should be addressed to the World Health Organization, 1211 Geneva 27, Switzerland,
attention: Technologies, Standards and Norms (TSN). Comments may also be submitted
electronically to the Responsible Officer: Dr Kai Gao, at email: [email protected].
© World Health Organization 2015
All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can
be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22
791 3264; fax: +41 22 791 4857; e-mail: [email protected]).
Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution –
should be addressed to WHO Press through the WHO web site:
(http://www.who.int/about/licensing/copyright_form/en/index.html).
The designations employed and the presentation of the material in this publication do not imply the expression of any
opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or
area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent
approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or
recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors
and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this
publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health
Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in
this publication.
WHO/BS/2015.2267
Page 2 of 39
Summary A collaborative study was conducted with an aim to establish the 1
st International Standard
(IS) for anti-human enterovirus A71 (EV71) serum (Human). Two candidate samples were
produced from plasma samples donated by healthy individuals in China and collected and
characterized by NIFDC. A third serum preparation containing low anti-EV71 antibody titre
was also produced with a view to be assessed as a WHO Reference Reagent. The serum
samples are intended to help laboratories standardize virus neutralization methods to measure
antibody levels against EV71 in human sera. These assays might be suitable for the
evaluation of the immunogenicity of EV71 vaccines and for the assessment of the
seroprevalence of human populations against EV71 virus. The serum samples were processed,
filled and freeze-dried at NIBSC. The study consisted of seventeen laboratories from UK,
USA, China, Taiwan , Japan and Malaysia ,which national control laboratories,
manufacturers of EV71 vaccines and public health laboratories were included. All
participants used their own in-house virus neutralization method and a challenge EV71 strain
provided by NIBSC. The study samples comprised the two serum candidates, namely 14/138
and 14/140, the low titre sample, 13/238, the Chinese National Standard (Liang et al, 2011),
four clinical sera from naturally infected individuals and a sample prepared with a mixture of
sera from volunteers who had received EV71 vaccine as part of a clinical trial. Both
candidates were included as coded duplicates and also as a single vial in liquid format.
Preliminary assays at NIBSC showed that all three serum samples exhibited good levels of
neutralizing antibodies against a wide range of EV71 strains of various genotypes. The
subsequent collaborative study showed that between laboratory variations in neutralization
titres were significantly reduced when values were expressed relative to those of either of the
two candidate sera. Stability studies were undertaken to further characterize the candidate
materials. Real time stability of samples maintained for 6 months at different temperatures
showed no significant loss of activity (relative to that at -20oC storage temperature) at
temperatures of +20oC and below. From these data, 14/140 is recommended as the 1
st IS for
anti-EV71 serum (Human) and 14/138 as a potential replacement for 14/140 in the future,
with an assigned unitage of 1,000 and 1,090 International Units (IU) of anti-EV71
neutralizing antibodies per vial, respectively. 13/238 was proposed as a WHO Reference
Reagent, serving as an assay control for EV71 neutralization assays with an assigned value of
300 IU per ampoule.
Introduction Vaccines for the effective prevention of Hand-Foot and Mouth disease (HFMD) caused by
EV71 are under development across South –East Asia (Li et al., 2014; Chong et al., 2015).
Quantification of anti-EV71 neutralizing antibodies in human sera is an important marker and
diagnostic tool in assessing the immune status of individuals. Such data are invaluable for the
evaluation of the immunogenicity of EV71 vaccines. With the surge in vaccine production it
has been recognized that there is a need to establish suitable reference standards to ensure
that methods used to measure the serum neutralizing activity or antibody levels against EV71
are accurate, sensitive and reproducible. This will contribute to the standardized assessment
of the quality and efficacy of vaccines used in immunization programs globally.
Standardized neutralization assays can also be used to estimate the seroprevalence of human
WHO/BS/2015.2267
Page 3 of 39
populations against EV71. The proposal for establishing the 1st IS of anti-EV71 serum
(Human) was endorsed by ECBS in 2012 (WHO TRS 980). Candidate materials were
identified among sixty two plasma samples donated by healthy individuals in China.
As it has been shown in a number of clinical and seroprevalence studies, the cross-reactivity
between EV71 strains of different genotypes is not easy to predict as antigenic variations
between viruses can be detected but does not have a clear pattern (Huang et al., 2013). For
this reason, EV71 strains representative of a wide range of B and C genotypes were used for
the initial characterization of the candidate serum samples. EV71 strains of C4, B2 and B4
genotypes are used for EV71 candidate inactivated vaccines that are at different stages of
clinical development and have been used in clinical trials in humans (Li et al., 2014; Chong et
al., 2015).
Aim of the study
The aim of the study was to characterize two candidate anti-EV71 sera in virus neutralization
assays to assess their suitability to be used as the 1st IS for anti-EV71 serum (Human). A
third serum preparation containing low anti-EV71 antibody titres was also evaluated as a
WHO Reference Reagent. Both reference materials are intended to help laboratories
standardizing virus neutralization methods.
Materials and Methods
Bulk materials and processing
Product summary
A donation of sixty-two plasma samples from healthy individuals with glutamic-pyruvic
transaminase (ALT) <25U, confirmed to be negative for HBsAg, HIV, HCV
and syphilis antibodies were assayed for EV71 neutralizing antibody (NTAb) titres. Twenty-
five plasmas which tested negative for Coxsackivirus A16 (CA16)-NTAb and positive for
EV71- NTAb were chosen to be pooled to produce the two high candidate IS and a low anti-
EV71 antibody reference. Ten plasmas with similar high levels of anti-EV71 neutralising
antibodies were selected to become the two high titre candidate standards and five plasmas
with similar levels low levels of antibody were selected for the low titre reference. The initial
screening of plasma suitability was performed at NIFDC. The final selection of plasma for
the candidate international references was performed in conjunction with NIBSC. The serum
samples were then processed, filled and freeze-dried at NIBSC.
Individual plasmas were shipped to NIBSC frozen on dry-ice and stored at -80oC until
processing. Aliquots (1ml) of each plasma were also sent for formulation purposes. The
samples were screened for safety markers by the NIBSC Blood Virology section and all
found to be negative for HBsAg, Anti HIV 1+2, HCV RNA NAT test and Anti-HCV, and
therefore suitable to serve as candidate International references.
A pilot trial fill was undertaken to validate if the defibrination method used was suitable for
the freeze drying of the filled product. There is little previous experience for the freeze
drying of EV71 serum and therefore it was important to establish a cycle that would give a
reliable and, stable product limiting the loss of EV71 NTAb activity. This was completed on
WHO/BS/2015.2267
Page 4 of 39
27/01/14. The three candidates gave yellowish, robust cake that remained intact on agitation.
The fill Coefficient of Variation (CV%) was 1.80, 1.21 and 1.49 for the two high and low
respectively. These figures are within the acceptable range for a product of this nature.
Moisture and oxygen levels were also within range. Ampoules from the pilot fills were also
tested by the NIBSC Biotherapeutics department for presence of thrombin. All samples tested
negative, validating the method used.
Defibrination and Pooling
Plasma samples were defrosted at +4oC prior to defibrination and pooling. Once thawed the
samples for each reference were pooled and aliquoted in 300ml volumes into 500ml sterile
blood bottles. They were treated with 10% CaCl2 (0.125 M) and incubated for 30 minutes at
37oC. The bottles were then placed at +4
oC overnight to form a clot. The liquid was removed
and the clot was squeezed to release any retained liquid. The clot was then returned to +4oC
overnight and the process of squeezing was repeated over several days. The serum was spun
at 4000rpm for 30 mins and the supernatant removed. The resulting sera were stored at +4oC
prior to filling and freeze drying.
Filling, Freeze-drying and Sealing
Filling was completed for all three candidates from a homogenous stirred bulks maintained at
+40C throughout the filling using a Bausch and Strobel AFV5090 machine. 3ml ampoules
were filled with 0.5ml of material and in-line samples. For every 90 ampoules filled 3
ampoules (4-5% of total filled ampoules) were taken for measurements of the fill volume.
Freeze-drying was carried out directly after filling using a 2 day cycle. After completion of
the freeze –drying the candidate materials were put at long term storage of -20oC.
Ampoules were sealed under boil-off gas from high purity liquid nitrogen (99.99%) and
measurement of the mean oxygen head space after sealing served as a measure of ampoule
integrity. The mean oxygen head space was measured non-invasively by frequency
modulated spectroscopy (FMS 760, Lighthouse Instruments, Charlottesville, USA). Residual
moisture content was measured using the colorimetric Karl Fischer method in a dry box
environment (Mitsubishi CA100, A1 Envirosciences, Cramlington, UK) with total moisture
expressed as a percentage of the mean dry weight of the ampoule contents.
Product summary details for each of the filled samples are shown in Table 1. Fill dates for the
candidate materials are detailed below:
Anti-EV71 serum Low (NIBSC 13/238) – 14/02/2014
Anti-EV71 serum High (NIBSC 14/138) – 29/05/2014
Anti-EV71 serum High (NIBSC 14/140) – 29/05/2014
Post filling testing of freeze-dried samples
One ampoule for each of the candidate ISs 14/138 and 14/140 from the beginning, middle
and end of the filling run were tested in three repeat assays to check the EV71 NTAb activity
after the freeze drying process. This testing was performed against the NIBSC C4 virus strain.
The GMT’s of the beginning, middle and end samples of 14/138 were; 724, 574 and 456, and
for 14/140 were; 512, 512 and 645. Overall there were no apparent losses in activity for each
of the candidates for any of the time points during the filling process. The filled material was
therefore fit to be used in the collaborative study as candidate ISs.
WHO/BS/2015.2267
Page 5 of 39
Study Samples
A total of thirteen samples were provided to participants. The samples were shipped in dry-
ice and storage at ≤ -70oC was recommended. Participants were provided with three
ampoules of sample A, B, D, E and F, two ampoules of samples H and I, one vial of sample T,
W, X, Y and Z.
A Sample Receipt Form was included with the study protocol to give feedback on the date of
the shipment and condition the samples were received. Instructions for Use and Material Data
Sheets were also provided.
There were no issues with the shipment and the receipt of samples, although one laboratory
reported later that their samples were received without dry-ice.
The study samples are listed below:
Low candidate for anti – EV71 antibodies, sample A
A collection of 5 plasmas from Chinese donations that had similar low EV71 antibody serum
titres and tested negative for CA16 antibodies, were pooled to produce this standard (NIBSC
-13/238).
WHO 1st candidate for anti – EV71 antibodies High, samples B and D
A collection of 5 plasmas from Chinese donations that had similar High EV71 antibody
serum titres and tested negative for CA16 antibodies were pooled to produce this standard
(NIBSC -14/138)
WHO 1st candidate for anti – EV71 antibodies High, samples E and F
A collection of 5 plasmas from Chinese donations that had similar High EV71 antibody
serum titres and tested negative for CA16 antibodies were pooled to produce this standard
(NIBSC -14/140)
NIFDC National anti – EV71 antibody standard, sample G
Produced and validated in a collaborative study in 2010: code 2010/No 0024. Produced from
a single plasma from a naturally infected donor with appropriate safety levels. Assigned
1,000 EV71 U/ml (NTAb units). Freeze –dried preparation and is reconstituted in 200ul
sterile glass distilled water. Custodian is NIFDC and the long term storage is -20oC.
WHO 1st candidates for anti – EV71 antibodies High liquid presentation, samples H and
I
Samples of 14/138 and 14/140 were reconstituted by NIBSC in 0.5ml Sterile distilled water
and frozen at -20oC prior to the study.
Human serum from EV71 vaccinees, sample T
10 sera from Chinese donors with more than 0.5ml volume and NTAb higher than 1:32 were
selected and pooled to produce vaccine-immunized sera for the collaborative study.
Clinical sera from naturally infected individuals, samples W, X and Z
Sera from healthy Chinese adults naturally infected with EV71.
WHO/BS/2015.2267
Page 6 of 39
Low titre EV71 serum, sample Y
Serum with low EV71 NTAb from an individual from a different geographical region
provided by NIBSC.
Challenge virus EV71 strains from most available B and C genotypes, representative of viruses that have been
widely circulating in the world in recent years (Chong et al., 2015), were selected for the
initial analysis of the sera. The virus panel covered a wide range of isolation dates and
geographical locations (Table 2). No genotype A or D viruses, that have circulated to a much
lesser extent in recent years, were available for this study. Viruses were kindly provided by
Dr Qunying Mao (NIFDC, China), Dr Hiro Shimizu (NIID, Japan) and Dr Harrie van der
Avoort (RIVM, The Netherlands). The C4 523 strain was chosen from the panel of viruses.
This particular strain is routinely used by laboratories in China for the NTAb test of EV71
and was shown to be a suitable challenge virus for the test based on the results from the
collaborative study for the establishment of the current Chinese National Standard (Liang et
al., 2011). This choice was further justified by the fact that most EV71 vaccines in advance
stages of clinical development (mostly in China) are manufactured using EV71 C4 strains
which have been shown to induce good levels of cross-reactive neutralizing antibodies
against a wide range of EV71 genotype B and C strains (Zhang et al., 2014). Participants
were provided with one vial of EV71 C4 523 strain for use as the main challenge virus for the
study. The decision to provide a common challenge virus for all participants was made with
a view to reduce the variability in neutralization results between laboratories. This C4 523
strain could serve as a future reference virus for neutralization assays if there is demand.
Laboratories 14 and 17 also used EV71 B4 C7/Osaka/1997 strain as a second challenge virus.
An EV71 B4 strain is used for vaccine production by at least one manufacturer in Taiwan (Li
et al., 2014; Chong et al., 2015).
Design of Collaborative Study
Participants
Twenty one laboratories were invited to participate in the study. Eighteen laboratories from
seven countries accepted to participate. They included two National Control laboratories, ten
manufacturers and five Public Health Institutes. Seventeen retuned data. They are referred to
by a code number, allocated at random, and not reflecting the order of listing in Appendix 1.
Study time-frame
The study samples were sent to participants mid-March 2015 and the coordinator requested
data to be returned by the 27th
April 2015. Due to issues with some participants requiring
permits, some study samples were sent late so the deadline for these participants was
extended. The majority of participants were able to return data by the deadline.
Study Plan
Participants were requested to:
WHO/BS/2015.2267
Page 7 of 39
- Follow recommended protocols for storage, reconstitution and preparation of dilutions of
the study samples.
- Determine the neutralization titre against EV71 of each of the 13 coded human sera in the
panel by performing three independent assays using their in-house method and RD cells if
possible.
- Use a fresh ampoule of samples A, B, D, E, and F for each assay.
- Use the EV71 C4 strain included in the panel as the challenge strain in the neutralization
assay (if participants routinely use a genotype B strain in the laboratory, they were asked
to also evaluate the panel of sera against an EV71 B virus strain as well).
Laboratory methods
Participants used the same basic methodology where the study samples were assayed for
EV71 neutralizing antibodies using a constant virus varying serum method using RD cells.
The main challenge virus strain was provided by the study coordinator. The challenge dose
recommended for the assay was between 1.0 – 3.0 log10 TCID50.
The assay method requires the serum and virus to be incubated in a 96 well. After an initial
incubation step the cell substrate is added and a further incubation step is required to allow
for the development of cytopathic effect (CPE). The assay is then read to determine the end
point dilution based on the last positive well showing CPE. Participants provided calculated
titres based on this method. Details of participant’s in-house methods can be found in Table
3.
Overall the methods were relatively consistent across parameters. Laboratories 11, 12 and 13
used only 4 days post infection for the development of CPE versus 7 days for all other
laboratories. The major variation is the use of the Plaque Reduction Neutralization Test
(PRNT) using Vero cells by Laboratory 15.RD cells were used by all participants except
laboratory 12 who used Vero cells to perform the study.
Participants included their in-house assay positive and negative controls and reported results.
Documentation of Study results
Participants were requested to report their results electronically using standard forms
provided by the coordinator. Results including potency calculations and statistical validity
criteria were to be sent using the Results Forms. The Raw Data Form provided a template so
that participants could document the scoring of the samples. Information on the method and
assay reagents used was also requested using the Method Form.
Statistical methods
For each sample, end point titres were based on the last positive well in a dilution series.
Titres were converted directly into relative potencies by dividing the titre value by that
obtained for the appropriate standard. Potencies relative to the two candidate high titre
WHO/BS/2015.2267
Page 8 of 39
standards, 14/138 and 14/140, were calculated relative to the geometric mean (GM) of the
results obtained for the coded duplicates (samples B and D for 14/138, samples E and F for
14/140). Mean estimates for each sample in each laboratory were taken as the geometric
mean (GM) of the three assays performed.
Variability in results (end point titres and relative potencies) between assays within
laboratories and between laboratories was assessed using geometric coefficients of variation
(GCV = {10s-1} ×100% where s is the standard deviation of the log10 transformed results),
within assay variation was assessed using the relative potencies of the coded duplicates for
the two candidate standards 14/138 and 14/140. Pooled GCVs across all laboratories have
been calculated for the clinical samples T, W, X and Y for the end points titres and the
potencies relative to the candidate standards.
Stability Studies
Samples of the candidate standards were stored at -150°C, -70°C, -20°C, +4°C, and +20°C
and tested at 1 and 6 months. Samples will be tested yearly to assess long term stability.
Samples were also placed at + 37°C and +45°C for up to one month and these were also
tested for EV71 NTAb.
The stability of candidate standards reconstituted in liquid form was also assessed. Ampoules
of the three candidate materials were reconstituted in 0.5ml of sterile glass distilled water and
maintained at +4°C or 20°C for a period up to four weeks.
Results
Preliminary characterization of serum samples
Virus stocks for this study were prepared by growth in cell cultures and titres were
established using a validated infectivity assay (TCID50) using RD cells. Nearly full genome
sequences of stock EV71 strains were obtained by deep sequencing analysis using the MiSeq
sequencing platform.
The donated serum samples were initially tested against four different EV71 genotype C4
strains and one CA16 virus at NIFDC. Data from this analysis were used to select the serum
samples that were used to produce the three candidate sera. The data shown in Table 4
represent the average for the pooled plasmas for each group expressed as GMT‘s against the
different EV71 viruses. All serum samples were negative against the CA16 virus (data not
shown). All serum samples showed lower neutralization titres against virus EV71-1 different
to those against EV71-2 to 4 strains. There is not a clear explanation for this result as all four
viruses were of the same genotype (C4), all from China and even EV71-1 to 3 strains were
obtained from the same outbreak in Anhui, China in 2008. However, mutations found at
capsid amino acids VP1-98, 145, 167 and 183 in EV71-1 strain might have an effect on the
antigenicity of this virus as they all locate at or close to antigenic site 1, near the 5-fold axis
of symmetry. This can explain, at least in part, the observed results.
Following plasma processing, filling and freeze-drying, the candidate serum samples were
tested against a panel of EV-71 viruses (Table 2) to check cross reactivity. The results
WHO/BS/2015.2267
Page 9 of 39
showed that all three serum preparations had neutralization activity against all virus strains
tested (Figure 1). Generally, all three serum preparations showed higher neutralization titres
against genotype C EV71 strains than they did against genotype B EV71 viruses although
differences for serum samples 13/238 and 14/140 were small. Differences were greater for
serum sample 14/138. All three sera showed the lowest neutralization titres against EV71 B1
71-17000 strain isolated in The Netherlands in 1971.
A large stock of EV71 C4 523 virus was prepared at NIBSC by growth in RD cells for
distribution to collaborative laboratories. The virus titre was given to participants as a guide,
and they were requested to verify that they could obtain a titre within +/-0.3log10 of the
estimate using their routine RD cells assay. Laboratories were asked to also test EV71
genotype B strains if available.
Results of collaborative study
Study data returned
Data were received from 17 participants who calculated end point titres for all samples using
their in-house EV71 NTAb method in 3 assays (Table 5A and Figure 2). Lab 7 returned two
sets of results from two different operators, but one set was only partially complete and was
excluded from further analysis. Labs 14 and 17 returned two sets of results using virus strains
B4 and C4 in each of them. Re-analysis of the assay raw data at NIBSC gave close agreement
to the results reported by participants and therefore the participant’s results were used for
subsequent analysis.
Intra and inter-assay variability
Relative potencies of the coded duplicate samples of 14/138 (B and D) and 14/140 (E and F)
were used to assess intra-assay variability and are shown in Figures 3 and 4, respectively.
With the exception of 14/140 in labs 12, 13 and 17, relative potencies were in the range [0.5,
2.0] in 97% of cases, showing a good level of intra-assay precision among participating
laboratories.
Inter-assay variability, as illustrated by the between-assay GCVs in Table 5A, ranged from
0% (no difference in results obtained for sample in all three assays) to 396% (16-fold
difference in results obtained for sample W by lab 2). Despite some instances of high inter-
assay variability, no further exclusions were made for the analysis presented in this report.
End point titres
Table 5B and Figure 5 summarise the calculated laboratory mean end point titre estimates.
With the exception of sample T, all between-laboratory GCVs were above 60%. The pooled
between-laboratory GCV for the clinical serum samples T, W, X and Y is 64%.
Potencies relative to 14/138 (samples coded B and D)
Table 6 and Figure 6 summarise potency estimates relative to 14/138 (samples coded B and
D). These show better agreement between laboratories than end point titres for all samples,
with the exception of sample Z which had the lowest titre of the samples tested. With the
exception of samples W and Z, between-laboratory GCVs were between 33% and 49%. The
pooled between-laboratory GCV for the clinical samples T, W, X and Y was reduced to 41%.
WHO/BS/2015.2267
Page 10 of 39
Potencies relative to 14/140 (samples coded E and F) Table 7 and Figure 7 summarise potency estimates relative to 14/140 (samples coded B and
D). These also show better agreement between laboratories than end point titres for all
samples, with the exception of sample T which showed an equivalent level of agreement
(GCV of 45% compared to 43%). With the exception of sample Z, the low titre sample,
between-laboratory GCVs were between 29% and 45%. The pooled between-laboratory GCV
for the clinical samples T, W, X and Y was reduced to 35%.
Comparison of methods using Vero and RD cells
Analysis of variance with Tukey’s multiple comparison test was used to compare the
differences in methodology used between laboratories, using log transformed potencies. The
analysis showed that there is no significant difference in using Vero cells compared to RD
cells for the EV71 NTAb test. The comparison shows that using a PRNT method with Vero
cells, give results at the low end of the range, but these are not significantly different from the
majority of other laboratories. Several laboratories use only 4 days post infection to score for
CPE which could impact on the end point titres. The analysis showed that these laboratories
were within the middle of the range so not significantly different compared to other methods.
Comment on data returned from Laboratory 7 for second operator
Comparison of the data between the two operators for laboratory 7 for samples A–F, H and I
were consistent between operators and across samples. The results for operator 2 were mid-
range for the spread of end point titres reported by participants for all samples.
Results for study samples using EV71 B4 strain as a challenge virus
A comparison was performed by calculating the ratio between neutralization titres against B4
and C4 viruses for each study sample using data from each laboratory. The analysis (Table 8
and Figure 8) showed that there was good correlation between the results obtained by
laboratories 14 and 17 using C4 and B4 strains. However, agreement between the two
laboratories was not as good for samples A, W, X and Z. This is likely because those samples
contain low antibody neutralization titres against both B4 and C4 strains so assay variability
would have a greater impact on the overall result. As shown during preliminary work at
NIBSC, all study samples showed good levels of neutralizing activity against both B4 and C4
EV71 strains. Neutralization titres against the B4 strain were generally lower than those
against the C4 strain, particularly for serum samples B, D and H (representing candidate
standard 14/138). The results likely reflect the serum composition as different individual
donors would have been exposed to different EV71 strains.
Stability study results
At the time of this report only data up to the 6 month time point are available for evaluation.
Three independent assays were performed at each temperature and time point, and potencies
relative to the -20°C baseline for all three candidates were obtained. Geometric means with
confidence limits are shown in Tables 9A, B and C. The data show that there is no significant
loss of activity at +4°C and +20°C (temperatures used during laboratory manipulation for
assays), relative to the -20°C baseline for any of the three candidates. A program to measure
real-time stability is ongoing by regularly measuring the potency of samples stored at -70°C,
-20°C and +4°C.
WHO/BS/2015.2267
Page 11 of 39
The stability of candidate standards reconstituted in liquid form was also assessed. Ampoules
of the three candidate materials that had been reconstituted in 0.5ml of sterile glass distilled
water and maintained at different temperatures were tested. Three independent assays were
performed at each temperature and time point, and potencies relative to that of an ampoule
stored at -20°C and freshly reconstituted were obtained for all three candidates. The data
show that there is no significant loss of activity for any of the reconstituted materials that had
been stored at -20, +4°C or +20 for any of the three candidate standards (Table 10).
Discussion Results shown in this study indicate that the candidate serum samples, particularly 14/140,
are suitable as reference standards to measure the neutralization activity in human sera
against a wide range of EV71 strains from different genotypes. Based on the lower overall
GCV for clinical samples relative to 14/140 and the higher level of cross-reactivity of this
serum, it was decided to recommend 14/140 as the 1st IS for anti-EV71 serum (Human) with
an assigned potency of 1,000 IU of anti-EV71 neutralizing antibodies/ampoule. Based on this
proposal, the candidate 14/138 has a potency of 1,090 IU of anti-EV71 neutralizing
antibodies/ampoule. The low titre reference 13/238 was found to be suitable as an assay
control for the neutralization test. Based on its mean relative potency it can be assigned a
unitage of 300 IU of anti-EV71 neutralizing antibodies/ampoule. Further collaborative
studies might be required to measure more accurately the neutralizing activity against any
EV71 strain other than the EV71 C4 523 virus analysed here.
The collaborative study data showed high GCVs across laboratories. This high variability is
expected due to the methodology used to assess neutralizing antibody in a cell based system.
However, once the data are expressed as relative potencies against the candidate materials,
the between laboratory GCVs were reduced.
Stability data for the candidate materials showed that up to six months the standards were
stable. However, more data needs to be generated to be able to establish a long term stability
profile. Stability data also showed that the candidate standards were also stable after
reconstitution and re-freezing, although a slight loss in potency might have occurred after
four weeks at +4°C or two weeks at +20°C for some samples.
The aims of this collaborative study have been met, and a candidate IS can be proposed with
an IU unitage. The study has also shown that the neutralizing antibody method used by
participants was a suitable tool to assess the study materials and that expressing data as
relative potencies improves between laboratory standardization. This is important as the role
of this IS is to ensure that methods used to measure the serum neutralizing activity or
antibody levels are accurate, sensitive and reproducible for the assessment of vaccines used in
immunization programs.
Commutability for the candidate serum samples for clinical samples has not been specifically
addressed in this collaborative study. To address this would require the reference material to
be evaluated in a range of assay methods, alongside all sample types for which it might be
used for the detection of EV71 Ab. However, the data presented in this report for several
clinical serum samples, which include samples with low, medium and high antibody content,
demonstrate that inter-laboratory agreement is improved when results are expressed as
relative potencies and so the 1st IS for anti-EV71 serum (Human) is fit for its intended use.
WHO/BS/2015.2267
Page 12 of 39
Recommendations It is proposed that the candidate 14/140 should be established as the 1
st IS for anti-EV71
serum (Human) to be used for the standardization of virus neutralization assays. The assigned
potency for this should be:
1,000 IU/ampoule
It is proposed that the candidate 14/138 should be retained as a potential
secondary/replacement IS for anti-EV71 serum (Human) to be used for the standardization of
virus neutralization assays. The assigned potency for this should be:
1,090 IU/ampoule
It is proposed that 13/238 should be ratified as a low anti-EV71 WHO Reference Reagent for
anti-EV71 serum (Human) to be used for the standardization of virus neutralization assays.
The assigned potency for this should be:
300 IU /ampoule
A summary of participant’s comments is provided in Appendix 2. A sample of the
Instructions for Use and the Material Safety Data sheet can be found in Appendix 3.
References - Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines.
2015. Clin Infect Dis. 60(5):797-803. doi: 10.1093/cid/ciu852.
- Huang ML, Chiang PS, Chia MY, Luo ST, Chang LY, et al. Cross-reactive neutralizing
antibody responses to enterovirus 71 infections in young children: implications for
vaccine development. 2013. PLoS Negl Trop Dis 7. doi: 10.1371/journal.pntd.0002067.
- Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. Development of enterovirus 71 vaccines: from
the lab bench to Phase III clinical trials. 2014. Expert Rev Vaccines.(5):609-18. doi:
10.1586/14760584.2014.897617.
- Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, Shen X, Wang
J. Establishing China's national standards of antigen content and neutralizing antibody
responses for evaluation of enterovirus 71 (EV71) vaccines. 2011. Vaccine. 29(52):9668-
74. doi: 10.1016/ j.vaccine.2011.10.018.
- Zhang H, An D, Liu W, Mao Q, Jin J, et al. 2014. Analysis of Cross-Reactive
Neutralizing Antibodies in Human HFMD Serum with an EV71 Pseudovirus-Based
Assay. PLOS ONE 9(6): e100545. doi:10.1371/journal.pone.0100545.
WHO/BS/2015.2267
Page 13 of 39
Table 1. Product Summary.
Product Summary of candidate standards used in the study
NIBSC code 13/238 14/138 14/140
Presentation 3ml DIN ampoules 3ml DIN ampoules 3ml DIN ampoules
No. of containers 3,508 5,004 5,010
Number of containers weighed 134 177 174
Validation of ampoule integrity Visual inspection plus
Oxygen headspace on
12 random samples
Visual inspection plus
Oxygen headspace on
12 random samples
Visual inspection plus
Oxygen headspace on 12
random samples
Sealing gas Nitrogen from liquid
Nitrogen 99.99% pure
Nitrogen from liquid
Nitrogen 99.99% pure
Nitrogen from liquid
Nitrogen 99.99% pure
Measured by Near Infra-Red
spectroscopy
Near Infra-Red
spectroscopy
Near Infra-Red
spectroscopy
Residual Moisture measured by Karl Fischer reagent Karl Fischer reagent Karl Fischer reagent
Mean fill mass 0.5g 0.5g 0.5g
CV fill mass 0.34% 0.44% 0.30%
Mean dry weight 0.04g 0.04g 0.04g
CV of dry weight 0.23% 0.82% 1.08%
Mean residual moisture 0.58% 0.70% 0.70%
CV residual moisture 14% 8% 11%
Mean oxygen headspace 0.37% 0.28% 0.35%
CV of oxygen headspace 34% 33% 21%
Date of fill 14/02/2014 29/05/2014 29/05/2014
Storage temperature -20˚C -20˚C -20˚C
Microbial contamination None detected None detected None detected
WHO/BS/2015.2267
Page 14 of 39
Table 2. List of EV71 strains in the panel.
Genotype EV71 Strain Year Location
B0 B0 (66-10857) 1966 Netherlands
B1 B1 (71-17000) 1971 Netherlands
B2 B2 (86-11316) 1986 Netherlands
B3 B3 (MAL-97-B3) 1996 Malaysia
B4 B4 (JPN-97-B4) 1997 Japan
C1 C1 (91-480) 1991 Netherlands
C2 C2 (36-92) 2007 Netherlands
C4 C4 (JPAN-3-C4) 2003 Japan
C4 C4 (China 523 NIBSC) 2007 China
C4 C4 (75-YAMAGATA) 2003 Japan
C5 C5 (E200525-TW) 2006 Taiwan
WHO/BS/2015.2267
Page 15 of 39
Table 3. Details of methods used by participants.
Lab
Code
Cell line
used Cell information
In-house
Positive
Serum
Controls
In-house
Negative
Serum
Controls
virus-serum
incubation
（hours & ℃）
CPE Assay
(Days & ℃）
1 RD 1.0-1.5E5 cells/well 2 1 37℃ for 2 hrs 37℃ for 7 days
2 RD 1.5E5 cells/well 1 1 37℃ for 2 hrs 37℃ for 7 days
3 RD 1.0E5 cells/well --- --- No information No information
4 RD 1.6-1.8E5 cells/well --- --- 37℃ for 2 hrs 37℃ for 7 days
5 RD 1.12-1.09E5 cells/well 1 1 36℃ for 2 hrs 36℃ for 7 days
6 RD 1.5E5 cells/well 1 --- 37℃ for 2 hrs 35℃ for 7 days
7 RD 1.5E5 cells/well 1 1 36.5℃ for 2 hrs 35℃ for 7 days
8 RD 1.0E5 cells/well 1 1 37℃ for 2 hrs 37℃ for 7 days
9 RD 1.5-2.0E5 cells/well 1 1 37℃ for 2 hrs 35℃ for 7 days
10 RD 2.0E5 cells/well 1 --- 37℃ for 2 hrs 35℃ for 7 days
11 RD 0.05E5 cells/well 1 --- 37℃ for 1 hrs 37℃ for 4 days
12 Vero 0.4E5 cells/well --- --- 37℃ for 1 hrs 37℃ for 4 days
13 RD 0.3E5 cells/well 1 --- 37℃ for 1 hrs 37℃ for 4 days
14 RD 1E5 cells/well 3 --- 35℃ for 2 hrs 35℃ for 7 days
15 Vero 1.5E5 cells/well --- --- 37℃ for 1 hrs 37℃ for 6 days
16 RD 0.3E5 cells/well 1 --- 37℃ for 1 hrs 37℃ for 7 days
17 RD 1.0E5 cells/well 1 --- 37℃ for 3 hrs 37℃ for 7 days
WHO/BS/2015.2267
Page 16 of 39
Table 4. Data for Candidate Materials tested against four strains of EV71 Virus.
EV71-1 EV71-2 EV71-3 EV71-4
High 1 247.4 524.2 750.1 653.0
High 2 198.6 536.7 861.7 653.0
Low 40.8 93.2 93.8 60.4
WHO/BS/2015.2267
Page 17 of 39
Table 5A. Neutralization results in all laboratories.
Lab Assay Sample Code
A B D E F G H I T W X Y Z
1 1 128 768 768 768 512 724 512 384 1024 128 128 128 32
2 128 768 768 512 768 512 768 384 768 96 90 96 32
3 128 768 512 768 768 512 512 512 768 96 128 96 32
GM 128 768 671 671 671 575 586 423 845 106 114 106 32
GCV 0 0 26 26 26 22 26 18 18 18 23 18 0
2 1 128 384 384 256 384 384 512 768 1024 48 48 48 8
2 512 1536 1536 1536 1536 1536 2048 1024 2048 768 768 768 16
3 384 2048 2048 3072 3072 2048 2048 1536 3072 768 768 768 32
GM 293 1065 1065 1065 1219 1065 1290 1065 1861 305 305 305 16
GCV 108 145 145 260 188 145 123 42 74 396 396 396 100
3 1 512 1024 1536 768 1024 1024 2048 2048 1536 128 256 256 48
2 256 512 512 512 512 1024 1024 1024 768 128 384 96 32
3 512 1024 768 1024 768 1024 1536 768 1024 192 192 128 48
GM 406 813 845 738 738 1024 1477 1172 1065 147 266 147 42
GCV 49 49 74 42 42 0 42 66 42 26 42 66 26
4 1 64 384 384 256 256 384 384 384 768 32 48 48 8
2 96 384 384 256 384 384 384 384 512 48 96 48 12
3 48 384 384 384 384 384 384 256 512 64 96 64 12
GM 67 384 384 293 335 384 384 335 586 46 76 53 10
GCV 42 0 0 26 26 0 0 26 26 42 49 18 26
5 1 384 512 1024 768 768 1024 1024 1024 1024 192 384 128 24
2 256 512 768 768 768 768 1024 1024 768 256 192 128 24
3 192 512 512 512 768 768 768 512 1024 96 96 48 16
GM 266 512 738 671 768 845 930 813 930 168 192 92 21
GCV 42 0 42 26 0 18 18 49 18 66 100 76 26
6 1 256 512 768 768 768 768 1024 768 768 128 128 96 24
2 192 512 768 512 768 768 768 768 512 96 128 128 24
3 128 512 512 384 512 768 768 512 512 96 96 96 24
GM 185 512 671 533 671 768 845 671 586 106 116 106 24
GCV 42 0 26 42 26 0 18 26 26 18 18 18 0
7-1 1 96 1024 768 2048 1536 768 768 1024 768 128 192 96 48
2 192 512 768 1024 768 768 1024 1024 768 128 128 192 48
3 256 1024 1536 1536 1024 512 1024 768 1024 128 192 128 48
GM 168 813 968 1477 1065 671 930 930 845 128 168 133 48
GCV 66 49 49 42 42 26 18 18 18 0 26 42 0
7-2 1 192 768 768 512 768 / 768 1536 / / / / /
2 256 512 512 768 768 / 768 1024 / / / / /
3 256 512 1024 1024 1536 / 1024 512 / / / / /
GM 233 586 738 738 968 / 845 930 / / / / /
GCV 18 26 42 42 49 / 18 74 / / / / /
8 1 128 512 512 512 768 768 768 1024 1024 96 128 96 32
2 192 512 512 512 384 768 1024 768 1024 128 192 96 24
3 192 768 512 512 384 384 384 768 1536 96 128 96 48
GM 168 586 512 512 484 610 671 845 1172 106 147 96 33
GCV 26 26 0 0 49 49 66 18 26 18 26 0 42
9
1 256 1024 768 768 1024 768 768 768 1024 256 384 256 48
2 256 512 1024 1024 1024 768 1024 768 1024 128 192 128 24
WHO/BS/2015.2267
Page 18 of 39
3 128 768 1024 768 1024 768 1024 768 1024 256 192 192 24
GM 203
738
930
845
1024
768
930
768
1024
203
242
185
30
GCV 49 42 18 18 0 0 18 0 0 49 49 42 49
10 1 128 768 512 384 768 384 768 512 768 96 128 96 32
2 192 768 512 512 384 512 1024 768 768 64 128 96 24
3 192 1024 512 384 768 512 768 512 768 128 128 128 32
GM 168 845 512 423 610 465 845 586 768 92 128 106 29
GCV 26 18 0 18 49 18 18 26 0 42 0 18 18
11 1 256 256 256 768 512 384 384 768 1024 192 96 96 48
2 256 512 512 512 1024 768 512 512 1536 192 192 256 64
3 192 384 512 512 512 512 256 512 1024 128 128 128 32
GM 233 369 406 586 645 533 369 586 1172 168 133 147 46
GCV 18 42 49 26 49 42 42 26 26 26 42 66 42
12 1 90 256 181 362 181 256 181 181 512 64 90 32 32
2 64 256 362 724 181 181 181 181 512 45 90 32 32
3 128 512 362 362 181 256 256 362 1024 90 128 45 32
GM 90 323 287 456 181 228 203 228 645 64 101 36 32
GCV 41 49 49 49 0 22 22 49 49 41 23 22 0
13 1 96 384 256 256 384 192 256 192 768 48 90 32 16
2 96 384 384 384 256 192 256 192 768 48 90 48 12
3 128 384 384 512 192 256 256 384 768 48 128 32 16
GM 106 384 335 369 266 211 256 242 768 48 101 37 15
GCV 18 0 26 42 42 18 0 49 0 0 23 26 18
14-1
C4
1 64 1024 512 512 256 512 1024 256 1024 64 128 32 8
2 128 1024 1024 512 256 512 512 256 1024 64 128 128 8
3 128 512 1024 512 256 256 512 512 1024 64 64 64 8
GM 102 813 813 512 256 406 645 323 1024 64 102 64 8
GCV 49 49 49 0 0 49 49 49 0 0 49 100 0
14-2
B4
1 64 128 128 256 256 512 128 256 512 32 64 64 8
2 64 64 256 512 256 128 64 128 256 32 128 32 8
3 64 128 256 256 256 256 128 128 256 32 128 32 8
GM 64 102 203 323 256 256 102 161 323 32 102 40 8
GCV 0 49 49 49 0 100 49 49 49 0 49 49 0
15 1 160 640 1280 1280 640 640 640 1280 1280 160 320 160 40
2 640 1280 1280 640 1280 640 640 640 1280 320 640 640 40
3 640 1280 1280 640 640 640 1280 640 1280 160 320 160 160
GM 403 1016 1280 806 806 640 806 806 1280 202 403 254 63
GCV 123 49 0 49 49 0 49 49 0 49 49 123 123
16 1 512 2048 1448 2048 1024 1448 1448 1448 4096 362 512 362 90
2 512 2048 1448 1448 1448 1448 1024 1448 724 256 362 362 45
3 362 2048 1448 1448 1448 2048 1448 1448 1448 181 362 362 90
GM 456 2048 1448 1625 1290 1625 1290 1448 1625 256 406 362 71
GCV 22 0 0 22 22 22 22 0 139 41 22 0 49
17 1 256 1448 724 1024 362 724 724 724 724 90 181 90 16
2 256 2048 1448 724 724 1024 1448 1024 2048 90 512 181 32
3 256 2048 1024 1448 2896 2896 724 2048 4096 90 362 256 45
GM 256 1824 1024 1024 912 1290 912 1149 1824 90 323 161 28
GCV 0 22 41 41 188 106 49 70 139 0 70 70 69
WHO/BS/2015.2267
Page 19 of 39
Table 5B. Laboratory geometric means end point titres.
Lab A B D E F G H I T W X Y Z
Lab 1 128 768 671 671 671 575 586 423 845 106 114 106 32
Lab 2 293 1065 1065 1065 1219 1065 1290 1065 1861 305 305 305 16
Lab 3 406 813 845 738 738 1024 1477 1172 1065 147 266 147 42
Lab 4 67 384 384 293 335 384 384 335 586 46 76 53 10
Lab 5 266 512 738 671 768 845 930 813 930 168 192 92 21
Lab 6 185 512 671 533 671 768 845 671 586 106 116 106 24
Lab 7-1 168 813 968 1477 1065 671 930 930 845 128 168 133 48
Lab 8 168 586 512 512 484 610 671 845 1172 106 147 96 33
Lab 9 203 738 930 845 1024 768 930 768 1024 203 242 185 30
Lab 10 168 845 512 423 610 465 845 586 768 92 128 106 29
Lab 11 228 364 406 575 645 512 362 575 1149 161 128 143 45
Lab 12 90 323 287 456 181 228 203 228 645 64 101 36 32
Lab 13 106 384 335 369 266 211 256 242 768 48 101 37 15
Lab 14-1 102 813 813 512 256 406 645 323 1024 64 102 64 8
Lab 15 403 1016 1280 806 806 640 806 806 1280 202 403 254 63
Lab 16 456 2048 1448 1625 1290 1625 1290 1448 1625 256 406 362 71
Lab 17 256 1824 1024 1024 912 1290 912 1149 1824 90 323 161 28
GM 189 707 686 666 614 621 692 637 995 117 170 115 28
GCV 74% 70% 61% 60% 78% 74% 76% 76% 43% 75% 70% 94% 82%
WHO/BS/2015.2267
Page 20 of 39
Table 6. Laboratory geometric mean potencies relative to 14/138 (samples coded B and D).
Lab A E F G H I T W X Y Z GM (E:F)
Lab 1 0.18 0.93 0.93 0.80 0.82 0.59 1.18 0.15 0.16 0.15 0.04 0.93
Lab 2 0.28 1.00 1.14 1.00 1.21 1.00 1.75 0.29 0.29 0.29 0.02 1.07
Lab 3 0.49 0.89 0.89 1.24 1.78 1.41 1.28 0.18 0.32 0.18 0.05 0.89
Lab 4 0.17 0.76 0.87 1.00 1.00 0.87 1.53 0.12 0.20 0.14 0.03 0.82
Lab 5 0.43 1.09 1.25 1.37 1.51 1.32 1.51 0.27 0.31 0.15 0.03 1.17
Lab 6 0.31 0.91 1.14 1.31 1.44 1.14 1.00 0.18 0.20 0.18 0.04 1.02
Lab 7-1 0.19 1.67 1.20 0.76 1.05 1.05 0.95 0.14 0.19 0.15 0.05 1.41
Lab 8 0.31 0.93 0.88 1.11 1.22 1.54 2.14 0.19 0.27 0.18 0.06 0.91
Lab 9 0.25 1.02 1.24 0.93 1.12 0.93 1.24 0.25 0.29 0.22 0.04 1.12
Lab 10 0.25 0.64 0.93 0.71 1.28 0.89 1.17 0.14 0.19 0.16 0.04 0.77
Lab 11 0.59 1.49 1.68 1.33 0.94 1.49 2.99 0.42 0.33 0.37 0.12 1.58
Lab 12 0.30 1.50 0.59 0.75 0.67 0.75 2.12 0.21 0.33 0.12 0.11 0.94
Lab 13 0.29 1.03 0.74 0.59 0.71 0.67 2.14 0.13 0.28 0.10 0.04 0.87
Lab 14-1 0.13 0.63 0.31 0.50 0.79 0.40 1.26 0.08 0.13 0.08 0.01 0.45
Lab 15 0.35 0.71 0.71 0.56 0.71 0.71 1.12 0.18 0.35 0.22 0.06 0.71
Lab 16 0.26 0.94 0.75 0.94 0.75 0.84 0.94 0.15 0.24 0.21 0.04 0.84
Lab 17 0.19 0.75 0.67 0.94 0.67 0.84 1.33 0.07 0.24 0.12 0.02 0.71
GM 0.27 0.96 0.88 0.89 0.99 0.91 1.43 0.17 0.24 0.17 0.04 0.92
GCV 49% 33% 46% 36% 36% 43% 39% 57% 34% 46% 85% 33%
WHO/BS/2015.2267
Page 21 of 39
Table 7. Laboratory geometric mean potencies relative 14/140 (samples coded E and F).
Lab A B D G H I T W X Y Z GM (B:D)
Lab 1 0.19 1.14 1.00 0.86 0.87 0.63 1.26 0.16 0.17 0.16 0.05 1.07
Lab 2 0.26 0.93 0.93 0.93 1.13 0.93 1.63 0.27 0.27 0.27 0.01 0.93
Lab 3 0.55 1.10 1.14 1.39 2.00 1.59 1.44 0.20 0.36 0.20 0.06 1.12
Lab 4 0.21 1.22 1.22 1.22 1.22 1.07 1.87 0.15 0.24 0.17 0.03 1.22
Lab 5 0.37 0.71 1.03 1.18 1.30 1.13 1.30 0.23 0.27 0.13 0.03 0.86
Lab 6 0.31 0.86 1.12 1.28 1.41 1.12 0.98 0.18 0.19 0.18 0.04 0.98
Lab 7-1 0.13 0.65 0.77 0.53 0.74 0.74 0.67 0.10 0.13 0.11 0.04 0.71
Lab 8 0.34 1.18 1.03 1.22 1.35 1.70 2.36 0.21 0.29 0.19 0.07 1.10
Lab 9 0.22 0.79 1.00 0.83 1.00 0.83 1.10 0.22 0.26 0.20 0.03 0.89
Lab 10 0.33 1.67 1.01 0.92 1.67 1.15 1.51 0.18 0.25 0.21 0.06 1.30
Lab 11 0.37 0.60 0.67 0.84 0.59 0.94 1.89 0.26 0.21 0.24 0.07 0.63
Lab 12 0.31 1.12 1.00 0.79 0.71 0.79 2.25 0.22 0.35 0.12 0.11 1.06
Lab 13 0.34 1.22 1.07 0.67 0.82 0.77 2.45 0.15 0.32 0.12 0.05 1.14
Lab 14-1 0.28 2.24 2.24 1.12 1.78 0.89 2.83 0.18 0.28 0.18 0.02 2.24
Lab 15 0.50 1.26 1.59 0.79 1.00 1.00 1.59 0.25 0.50 0.31 0.08 1.41
Lab 16 0.31 1.41 1.00 1.12 0.89 1.00 1.12 0.18 0.28 0.25 0.05 1.19
Lab 17 0.26 1.89 1.06 1.33 0.94 1.19 1.89 0.09 0.33 0.17 0.03 1.41
GM 0.30 1.11 1.07 0.97 1.08 1.00 1.56 0.18 0.27 0.18 0.04 1.09
GCV 41% 44% 30% 30% 41% 29% 45% 35% 36% 35% 66% 33%
WHO/BS/2015.2267
Page 22 of 39
Table 8. Neutralization titres using B4 and C4EV71 strains data for laboratories 14 and 17.
B4 Virus Strain
Lab code Assay A B D E F G H I T W X Y Z
17
1 64 181 128 362 362 362 128 362 362 90 181 90 16
2 128 362 724 724 724 512 362 512 512 128 181 90 22
GM 90.5 256 304.4 511.9 511.9 430.5 215.3 430.5 430.5 107.3 181 90 18.8
14
1 64 128 128 256 256 512 128 256 512 32 64 64 8
2 64 64 256 512 256 128 64 128 256 32 128 32 8
3 64 128 256 256 256 256 128 128 256 32 128 32 8
GM 64 101.6 203.2 322.5 256 256 101.6 161.3 322.5 32 101.6 40.3 8
C4 Virus Strain
17
1 256 1448 724 1024 362 724 724 724 724 90 181 90 16
2 256 2048 1448 724 724 1024 1448 1024 2048 90 512 181 32
GM 256 1748 1086 874 543 874 1086 874 1386 90 347 136 28.5
14
1 64 1024 512 512 256 512 1024 256 1024 64 128 32 8
2 128 1024 1024 512 256 512 512 256 1024 64 128 128 8
3 128 512 1024 512 256 256 512 512 1024 64 64 64 8
GM 101.6 812.7 812.7 512 256 406.4 645.1 322.5 1024 64 101.6 64 8
Ratio between strains (%)
lab 17 35% 15% 28% 59% 94% 49% 20% 49% 31% 119% 52% 66% 66%
lab 14 63% 13% 25% 63% 100% 63% 16% 50% 31% 50% 100% 63% 100%
Stability studies
WHO/BS/2015.2267
Page 23 of 39
Table 9A. Potencies of 13/238 relative to -20oC sample (%).
Temp
Time
(months) Assay 1 Assay 2 Assay 3
GM
(Overall) LCL UCL
-20°C 1 100 100 100 100 - -
-20°C 6 100 100 100 100 - -
+4°C 1 141 100 141 126 77 205
+4°C 6 100 100 70 89 54 147
+20°C 1 141 141 141 141 139 143
+20°C 6 100 141 70 100 42 238
Table 9B. Potencies of 14/138 relative to -20oC sample (%).
Table 9C. Potencies of 14/140 relative to -20oC sample (%).
Temp
Time
(months) Assay 1 Assay 2 Assay 3
GM
(Overall) LCL UCL
-20°C 1 100 100 100 100 - -
-20°C 6 100 100 100 100 - -
+4°C 1 100 200 50 100 18 559
+4°C 6 67 50 141 78 21 295
+20°C 1 71 200 71 100 23 444
+20°C 6 133 71 200 124 34 454
Temp
Time
(months) Assay 1 Assay 2 Assay 3
GM
(Overall) LCL UCL
-20°C 1 100 100 100 100 - -
-20°C 6 100 100 100 100 - -
+4°C 1 100 50 71 71 30 167
+4°C 6 53 71 141 81 23 283
+20°C 1 141 141 100 126 77 207
+20°C 6 100 71 71 79 48 130
WHO/BS/2015.2267
Page 24 of 39
Table 10. Stability after reconstitution. Potencies of 13/238, 14/138 and 14/140 relative to -
20oC sample (%) reconstituted on day of assay.
Temp
Time
(weeks) 13/238 14/138 14/140
-20°C 4 178 112 141
+4°C 1 112 89 126
+4°C 4 71 79 71
+20°C 1 102 100 79
+20°C 2 126 63 79
+20°C 4 126 79 71
WHO/BS/2015.2267
Page 25 of 39
Figure 1. Data for the candidate samples tested against a panel of EV-71 virus strains.
WHO/BS/2015.2267
Page 26 of 39
Figure 2. Plot of all log geometric means across all samples for each laboratory.
Sample ZYXWTIHGFEDBA
3.5
3.0
2.5
2.0
1.5
1.0
En
d P
oin
t
Lab 2Lab 3Lab 4Lab 5Lab 6Lab 7-1Lab 8Lab 9
Lab 1Lab 10Lab 11Lab 12Lab 13Lab 14-1Lab 15Lab 16Lab 17
Lab
WHO/BS/2015.2267
Page 27 of 39
Figure 3. Relative potencies of coded duplicate samples B and D.
17
16
15
14-1
13
12
11
10
09
08
07-1
06
05
04
03
02
01
421.5
1.331
0.75
0.670.
50.25
Lab
Ratio of B to D
WHO/BS/2015.2267
Page 28 of 39
Figure 4. Relative potencies of coded duplicate samples E and F.
17
16
15
14-1
13
12
11
10
09
08
07-1
06
05
04
03
02
01
421.5
1.331
0.75
0.670.
50.25
Lab
Ratio of E to F
WHO/BS/2015.2267
Page 29 of 39
Figure 5. Laboratories mean end point titres (with overall means shown in colour).
ZYXWTIH
GM
(E:F)
GM
(B:D
)GFEDBA
10000
1000
100
10
1
Sample
En
d P
oin
t T
iter
WHO/BS/2015.2267
Page 30 of 39
Figure 6. Laboratories mean potencies relative to 14/138 (with overall means shown in
colour).
ZYXWTIH
GM
(E:F)
GM
(B:D
)GFEDBA
10
1
0.01
0.01
0.001
Sample
Po
ten
cy R
ela
tive t
o 1
4/1
38
WHO/BS/2015.2267
Page 31 of 39
Figure 7. Laboratories mean potencies relative to 14/140 (with overall means shown in
colour).
ZYXWTIH
GM
(E:F)
GM
(B:D
)GFEDBA
10
1
0.01
0.01
0.001
Sample
Po
ten
cy R
ela
tive t
o 1
4/1
40
WHO/BS/2015.2267
Page 32 of 39
Figure 8. Ratio between neutralization titres against B4 and C4 viruses.
0%
20%
40%
60%
80%
100%
120%
140%
A B D E F G H I T W X Y Z
NT
ab
rati
o b
etw
een
B4 a
nd
C4 s
train
s (%
)
Serum sample
Lab 17
Lab 14
WHO/BS/2015.2267
Page 33 of 39
Appendix 1
List of Collaborative Study Participants
Dr Qunying Mao
National Institute of Food and Drugs
Control
Beijing
China
Dr Zhenping Li
Beijing Zhifei Lvzhu Biopharamaceuticals
Ctd.
Beijing
China
Dr Zhongping Xie
Institute of Medical Biology (IMB)
CAMS, PUNC,
China
Dr Xin Tong
Shanghai Zerum Biotechnology Co Ltd.
Shanghai,
China
Dr Xiuling Li
National Vaccine and Serum Institute
Beijing,
China
Dr Xianwu Zeng
Chengdu Institute of Biologicals Products Co
Ltd.
Sichuan Province.
China
Dr Yaling Hu
Sinovac Biotech Ltd
Beijing,
China
Dr Shuo Shen.
Wuhan Institute of Biological Products Co,
Ltd.
Wuhan, Hubei.
China
Dr Wen-qi An
Hualan Biological Engineering Inc,
Xinxiang, Henan,
China
Dr Xiangzhong Ye.
Beijing Wantai Biological Pharmacy
Enterprise Co, Ltd.
Beijing
China
Dr Qinjian Zhao
National Institute of Diagnostics and
Vaccine Development in Infections
Diseases.
Xiamen University
Xiamen, Fujian
China
Dr Yi-Chen Yang.
Food and Drug Administration,
Taipei City
Taiwan
WHO/BS/2015.2267
Page 34 of 39
Dr Min-Shi Lee.
National Health Research Institute
Zhunan, Miaoli County.
Taiwan.
Dr Hiroyuki Shimizu.
National Institute of Infectious Diseases
Tokyo
Japan.
Dr Jane Cardosa
Sentinext Therapeutics
Bayan, Lepas, Penang,
Malaysia
Dr Subash Das.
Takeda Vaccines Inc.
Madison, Wisconsin.
USA
Mrs Laura Crawt
National Institute of Biological
Standardization and Control.
London.
UK
WHO/BS/2015.2267
Page 35 of 39
Appendix 2
Summary of Participants comments on the report
Laboratory 2, 3, 5, 6, 7, 8, 9, 10, 11, 13, 16.
No comments received. This indicates that participants were in agreement with the report
recommendations.
Laboratory 4, 12,
Replied but had no comments.
Laboratory 15
One small editorial change requested. No major comments on recommendation. Final draft
revised.
Laboratory 14
In agreement with recommendation.
Supplied some extra information for the B4 data.
Laboratory 1
In agreement with recommendation.
WHO/BS/2015.2267
Page 36 of 39
Appendix 3
Proposed Instructions for use
1
st WHO International standards for anti-EV71 serum (Human)
NIBSC code 14/140
Version 01, 19/06/2015
“This material is not for in vitro diagnostic use”
1. INTRODUCTION
This preparation was established by the WHO Expert Committee on Biological
Standardisation in 2015 as the 1st International Standard for anti-EV71 serum (Human). It
was shown to be suitable for the standardization of virus neutralization methods to measure
antibody levels against EV71 in human sera. The preparation is a freeze-dried blend and has
been tested for the absence of adventitious agents.
2. UNITAGE
1,000 International Units of anti-EV71 neutralizing antibodies per ampoule.
3. CAUTION
THIS PREPARATION IS NOT FOR ADMINISTRATION TO HUMANS.
This preparation has been processed under clean controlled conditions but cannot be
guaranteed sterile. As with all materials of biological origin, this preparation should be
regarded as potentially hazardous to health. It should be used and discarded according to
your own laboratory's safety procedures. Such safety procedures probably will include the
wearing of protective gloves and avoiding the generation of aerosols. Care should be
exercised in opening ampoules or vials, to avoid cuts.
4. DIRECTIONS FOR OPENING THE DIN AMPOULE
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem
joins the wider ampoule body. Tap the ampoule gently to collect the material at the bottom
(labelled) end. Ensure that the disposable ampoule safety breaker provided is pushed down on
the stem of the ampoule and against the shoulder of the ampoule body. Hold the body of the
ampoule in one hand and the disposable ampoule breaker covering the ampoule stem between
the thumb and first finger of the other hand. Apply a bending force to open the ampoule at the
coloured stress point, primarily using the hand holding the plastic collar.
Care should be taken to avoid cuts and projectile glass fragments that might enter the eyes,
for example, by the use of suitable gloves and an eye shield. Take care that no material is lost
from the ampoule and no glass falls into the ampoule. Within the ampoule is dry nitrogen gas
at slightly less than atmospheric pressure. A new disposable ampoule breaker is provided
with each DIN ampoule.
5. USE OF AMPOULED MATERIAL
WHO/BS/2015.2267
Page 37 of 39
The 1st WHO International Standard for anti-EV71 serum (Human) should be used to help
laboratories standardize virus neutralization methods to measure antibody levels against
EV71 in human sera. These assays might be suitable for the evaluation of the
immunogenicity of EV71 vaccines and for the assessment of the seroprevalence of human
populations against EV71 virus.
Unopened ampoules should be stored at ≤ -20°C. Ampoules should be reconstituted on the
day of the assay by adding exactly 0.5 ml of pure sterile distilled water. To remove the
reagent from the ampoule it is necessary to use some form of transfer pipette rather than a
volumetric pipette. The contents of the ampoules should not be assumed to be sterile.
This material is supplied for use in its final form and must not be further diluted other than as
required for individual assay procedures. Each ampoule/vial is intended to be used only once.
The vial should be opened as directed in section 4.
Please note that the 1st IS is provided as a reagent for calibrating your own in-house reference
material(s). With this in mind recipients should remember that the supply of this reagent will be
limited to 3 vials per organization per year.
6. STABILITY
It is the policy of WHO not to assign an expiry date to their international reference materials.
They remain valid with the assigned potency and status until withdrawn or amended.
Reference materials are held at NIBSC with assured, temperature-controlled storage facilities.
Reference Materials should be stored on receipt as indicated on the label. Users should
determine the stability of the material according to their own method of preparation, storage
and use.
NIBSC follows the policy of WHO with respect to its reference materials.
Users who have data supporting any deterioration in the characteristics of any reference
preparation are encouraged to contact NIBSC.
7. CITATION
In all publications, including data sheets, in which this material is referenced, it is important
that the title of the preparation, the NIBSC code number, and the name and address of NIBSC
are cited and cited correctly.
8. PRODUCT LIABILITY AND LOSS
8.1 Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and
Conditions for the Supply of Materials
(http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) (“Conditions”) apply
to the exclusion of all other terms and are hereby incorporated into this document by
reference.
8.2 Unless the context otherwise requires, the definitions in the Conditions shall apply.
8.3 Nothing in this document or the Conditions shall limit or exclude NIBSC’s liability
for fraud or fraudulent misrepresentation, death or personal injury caused by its
negligence, or the negligence of its employees.
WHO/BS/2015.2267
Page 38 of 39
8.4 Subject to clause 8.3:
8.4.1 NIBSC shall under no circumstances whatsoever be liable to the Recipient,
whether in contract, tort (including negligence), breach of statutory duty, or
otherwise, for any loss of data, loss of profit, loss of business or goodwill, or
any indirect or consequential loss or damage suffered or incurred by the
Recipient arising in relation to the supply of the Materials or the use, keeping,
production or disposal of the Materials or any waste products arising from the
use thereof by the Recipient or by any other person; and
8.4.2 NIBSC’s total liability to the Recipient in respect of all other losses arising
under or in connection with the Contract, whether in contract, tort (including
negligence), breach of statutory duty, or otherwise, shall in no circumstances
exceed 100% of the fees paid to NIBSC for the Materials.
8.5 The Recipient shall defend, indemnify and hold NIBSC, its officers, employees and
agents harmless against any loss, claim, damage or liability including reasonable legal
costs and fees (of whatsoever kind or nature) made against NIBSC which may arise as
a result of the wilful act, omission or negligence of the Recipient or its employees, the
breach of any of the terms of the Contract, or the use, keeping, production or disposal
of the Materials or any waste products arising from the use thereof by the Recipient or
on its behalf.
WHO/BS/2015.2267
Page 39 of 39
MATERIAL SAFETY SHEET
Physical properties (at room temperature)
Physical appearance Samples 14/140
Freeze dried and has a small white/yellowish cake
Fire hazard None
Chemical properties
Stable Yes Corrosive: No
Hygroscopic Yes Oxidising: No
Flammable No Irritant: No
Other (specify) Contains material of human origin(EV 71 antibodies)
Handling: See caution, section 1
Toxicological properties
Effects of inhalation: Not established, avoid inhalation
Effects of ingestion: Not established, avoid ingestion
Effects of skin absorption: Not established, avoid contact with skin
Suggested First Aid
Inhalation: Seek medical advice
Ingestion: Seek medical advice
Contact with eyes: Wash with copious amounts of water. Seek medical advice.
Contact with skin: Wash thoroughly with water.
Action on Spillage and Method of Disposal
Spillage of ampoule contents should be taken up with absorbent material wetted with a virucidal
agent. Rinse area with a virucidal agent followed by water.
Absorbent materials used to treat spillage should be treated as biologically hazardous waste.
